Bye bye gadolinium! PRIME demonstrates bpMRI as good as mpMRI

Big news today with the publication in JAMA of the eagerly anticipated PRIME study, a prospective multicentre trial comparing biparametric (bp) with multiparametric (mp) MRI in men suspected of having prostate cancer. Of course, mpMRI includes contrast enhanced sequences following injection of gadolinium, adding time, cost, plus the burden of gadolinium to bpMRI, and there have been suggestions that bpMRI may be just as effective as mpMRI for detecting clinically significant prostate cancer. ...